COTA Increases Cross-Industry Support With the Addition of Celgene, Foundation Medicine, Inc., HealthScape Advisors and Novartis as Strategic Investors

NEW YORK, NY--(Marketwired - May 24, 2016) -  COTA Inc., a health care informatics and precision analytics company, today announced the addition of several strategic investors to accelerate its mission of making the best care clear. New investors include leading life science companies Celgene and Novartis, molecular information company Foundation Medicine, Inc. and health management consultant firm HealthScape Advisors.

COTA demonstrates increasing cross-industry representation by continuing to raise capital and partner with organizations in the health care discovery, development, delivery and payment sectors. These latest additions join the company's current investor group, composed of the Hackensack University Health Network, the health insurance company Horizon Blue Cross Blue Shield of New Jersey, health care analytics provider Med-Metrix and the multistate oncology practice Regional Cancer Care Associates.

"It is a great validation that leading companies Celgene, Foundation Medicine, HealthScape and Novartis support COTA's mission and share our commitment to improving the health and well-being of patients," said Eric Schultz, chief executive officer of COTA. "Our unique approach and real-world platform help physicians optimize treatment, ultimately facilitating the transition to value-based medicine, and help to ensure the right care for every patient, every time."

Each year in the United States, it is estimated that $870 billion is wasted on inappropriate and/or unnecessary care -- an amount that represents 5 percent of the entire U.S. gross domestic product. COTA helps reduce costs while improving outcomes by identifying the best treatments for each patient, helping to eliminate ineffective care. The company builds and analyzes research-grade, real-world data and harnesses the power of its patented COTA Nodal Address (CNA) classification system -- which precisely categorizes patient factors, types of diseases and intended therapies -- enabling better decisions.

"The cross-industry support COTA has gained allows us to provide the clearest path of care for each patient battling diseases like cancer, helping them live longer and fuller lives," said Andrew L. Pecora, M.D., FACP, CPE, founder and executive chairman of COTA and chief innovations officer of Hackensack University Health Network. "By bringing together multiple constituents across the health care industry, we are able to bridge precision medicine with precision analytics to address the problems of affordability and access and facilitate the acceleration of drug development and molecular-based diagnostic testing, ultimately leading to better patient outcomes."

The announcement of these strategic investors comes shortly after the recent addition of Dr. Donald Berwick, the former administrator of the Centers for Medicare and Medicaid Services (CMS), to COTA's board of directors.

For more information on COTA and how it is reshaping health care and making the best care clear, visit www.oncota.com

About COTA, Inc.
COTA is the health care informatics and precision analytics company that builds research-grade, real-world data to exponentially improve outcomes, reduce cost and ensure the right care for the right patient every time. The patented COTA Nodal Address System (CNA) is the first and only digital classification system that transforms prognostically significant variables into a digital code -- precisely categorizing patient factors, their diseases and intended therapies to measure treatment outcomes, identify variances in care and enable quality benchmarking, research, discovery and the transition to value-based medicine. For more information, please visit www.oncota.com. COTA - Best Care Made Clear.™